Bladder leaks or pelvic pressure can disrupt everyday life—but they’re common, treatable conditions. Learn how a ...
Physician who writes about the rising rates of cancer in young adults. This voice experience is generated by AI. Learn more.
The exploratory phase 2 study showed that neoadjuvant sacituzumab govitecan combined with pembrolizumab has some efficacy in patients with muscle-invasive bladder cancer, including those choosing a ...
The bundle offers a discount of $10 compared to subscribing to each individually. The bundle offers a discount of $10 compared to subscribing to each individually. is a news writer covering all things ...
In children hospitalised with acute severe ulcerative colitis on intravenous corticosteroids, intestinal ultrasound (IUS) parameters such as colonic wall thickness (CWT) were associated with ...
Universal ultrasound scan around 35-36 weeks detected 63% of neonates born severely small for gestational age (SGA), yet most stillbirths and neonatal complications occurred in foetuses classified as ...
Actress Katherine Heigl has been openly talking about female bladder leaks in ads for Poise pads since December 2024, and now football great Deion Sanders is doing the same for male bladder leaks in ...
Last month, Anker debuted its new Prime 3-in-1 Wireless Charging Station with a launch discount on Amazon. This deal has gotten even better today, with the accessory marked down to $115.99, down from ...
Please provide your email address to receive an email when new articles are posted on . Neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin significantly benefited patients with ...
A single-arm, multicenter Dutch phase 2 study enrolled cT2–T4aN0–2M0 patients (ECOG 0–1) and used induction dual checkpoint blockade followed by mitomycin/fluoropyrimidine-based chemoradiotherapy.
More than 30 police officers (33 to be exact) clocked $400,000 or more last year with a combination of detail and overtime pay, with a few other categories peppered in. The top earner for 2025 was BPD ...
Event-free survival improved with EV/pembro: median not reached vs 48.5 months, and 24‑month EFS 79.4% vs 66.2% with cisplatin/gemcitabine. Overall survival separated early (24‑month 86.9% vs 81.3%), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results